Acceso a los anticoagulantes de acción directa en España

Q4 Medicine
José Luis Segú
{"title":"Acceso a los anticoagulantes de acción directa en España","authors":"José Luis Segú","doi":"10.1016/S1131-3587(16)30016-4","DOIUrl":null,"url":null,"abstract":"<div><p>In Spain, new oral anticoagulants are used in fewer than 20% of patients with nonvalvular atrial fibrillation. This is lower than the rate observed in comparable countries and lower than that expected given current official recommendations and given the number of patients known to lie outside the therapeutic range while taking vitamin-K antagonists. This article provides an overview of the possible causes of the apparently low use of new oral anticoagulants in Spain. A number of distinct barriers have been documented that affect individuals involved in treatment decision-making (i.e. patients and health-care professionals and payers). The most relevant explanatory factors appear to be resistance to change by patients and health-care professionals, prescription being restricted to particular specialists, and the variation in policies affecting access to drugs between different Spanish autonomous regions. The causative factor that appears to best explain differing access to new oral anticoagulants in the Spanish National Health System is the impact of these drugs on the health budget. In particular, difficulties have been created by the absence of a coherent common management framework that takes responsibility for both the decision to fund an innovative treatment and the budgetary implications of its use. The effectiveness of a particular type of therapy does not imply that it will be “possible” to fund it at any given time, given that it is always legitimate to limit its use if decision-making is transparent and based on clear criteria. However, keeping alive, mostly nonexistent, technical uncertainties does not help solve the problem and casts doubt on the credibility of the evaluation process.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30016-4","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358716300164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 8

Abstract

In Spain, new oral anticoagulants are used in fewer than 20% of patients with nonvalvular atrial fibrillation. This is lower than the rate observed in comparable countries and lower than that expected given current official recommendations and given the number of patients known to lie outside the therapeutic range while taking vitamin-K antagonists. This article provides an overview of the possible causes of the apparently low use of new oral anticoagulants in Spain. A number of distinct barriers have been documented that affect individuals involved in treatment decision-making (i.e. patients and health-care professionals and payers). The most relevant explanatory factors appear to be resistance to change by patients and health-care professionals, prescription being restricted to particular specialists, and the variation in policies affecting access to drugs between different Spanish autonomous regions. The causative factor that appears to best explain differing access to new oral anticoagulants in the Spanish National Health System is the impact of these drugs on the health budget. In particular, difficulties have been created by the absence of a coherent common management framework that takes responsibility for both the decision to fund an innovative treatment and the budgetary implications of its use. The effectiveness of a particular type of therapy does not imply that it will be “possible” to fund it at any given time, given that it is always legitimate to limit its use if decision-making is transparent and based on clear criteria. However, keeping alive, mostly nonexistent, technical uncertainties does not help solve the problem and casts doubt on the credibility of the evaluation process.

在西班牙获得直接作用抗凝剂
在西班牙,只有不到20%的非瓣膜性心房颤动患者使用新的口服抗凝剂。这低于在可比较国家观察到的比率,也低于根据目前官方建议和已知在服用维生素k拮抗剂时超出治疗范围的患者数量所预期的比率。本文概述了西班牙新型口服抗凝剂明显低使用率的可能原因。已经记录了影响参与治疗决策的个人(即患者、保健专业人员和付款人)的一些明显障碍。最相关的解释因素似乎是患者和保健专业人员对变革的抵制,处方仅限于特定专家,以及影响西班牙不同自治区之间获得药物的政策不同。在西班牙国家卫生系统中,对新型口服抗凝剂的不同获取途径的致病因素似乎是这些药物对卫生预算的影响。特别是,由于缺乏一个协调一致的共同管理框架来负责为创新治疗提供资金的决定及其使用所涉预算问题,因此造成了困难。一种特定类型疗法的有效性并不意味着在任何时候都“可能”为其提供资金,因为如果决策是透明的并基于明确的标准,限制其使用总是合法的。然而,保留技术上的不确定性(大多是不存在的)无助于解决问题,并使人们对评估过程的可信度产生怀疑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista Espanola de Cardiologia Suplementos
Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.20
自引率
0.00%
发文量
1
期刊介绍: Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信